Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024...
Ericsson (NASDAQ:ERIC) – Ericsson reported better-than-expected profits, driven by a rebound in 5G equipment demand in North America. Net sales fell 4% to $5.92 billion but surpassed...
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, Oct. 14, 2024 Board Has Determined That...
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis PR Newswire WASHINGTON, Sept. 19, 2024 WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference PR Newswire WASHINGTON, Sept. 11, 2024 WASHINGTON, Sept. 11, 2024 /PRNewswire/ --Β Vanda...
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference PR Newswire WASHINGTON, Sept. 4, 2024 WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Vanda...
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference PR Newswire WASHINGTON, Aug. 29, 2024 WASHINGTON, Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1453 | 3.11822649527 | 4.6597 | 4.9 | 4.56 | 496050 | 4.73690898 | CS |
4 | 0.305 | 6.77777777778 | 4.5 | 5.3 | 4.35 | 691597 | 4.75495404 | CS |
12 | -0.305 | -5.9686888454 | 5.11 | 5.525 | 4.35 | 564491 | 4.88587709 | CS |
26 | -0.195 | -3.9 | 5 | 6.75 | 4.35 | 852825 | 5.46510606 | CS |
52 | 0.265 | 5.83700440529 | 4.54 | 6.75 | 3.295 | 1247393 | 4.82804622 | CS |
156 | -13.125 | -73.2013385388 | 17.93 | 18.45 | 3.295 | 832860 | 6.59778698 | CS |
260 | -8.695 | -64.4074074074 | 13.5 | 21.8627 | 3.295 | 715091 | 8.87253903 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.